Overview

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Status:
Recruiting
Trial end date:
2022-04-15
Target enrollment:
Participant gender:
Summary
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
NRG Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carboplatin